ZA200301465B - Vaccine composition comprising an antigen and a peptide having adjuvant properties. - Google Patents

Vaccine composition comprising an antigen and a peptide having adjuvant properties. Download PDF

Info

Publication number: ZA200301465B
Authority: ZA; South Africa
Prior art keywords: peptide; amino acid; vaccine according; acid residues; antigen
Prior art date: 2000-10-18

Application number

ZA200301465A

Other languages

English (en)

Inventor

Joerg Fritz

Frank Mattner

Wolfgang Zauner

Eszter Nagy

Michael Buschle

Original Assignee

Intercell Biomedizinische Forschungs & Entwicklungs Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-18

Filing date

2003-02-24

Publication date

2004-02-24

2003-02-24 Application filed by Intercell Biomedizinische Forschungs & Entwicklungs Gmbh filed Critical Intercell Biomedizinische Forschungs & Entwicklungs Gmbh

2004-02-24 Publication of ZA200301465B publication Critical patent/ZA200301465B/en

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims description 199
239000000427 antigen Substances 0.000 title claims description 86
108091007433 antigens Proteins 0.000 title claims description 86
102000036639 antigens Human genes 0.000 title claims description 86
229960005486 vaccine Drugs 0.000 title claims description 52
239000002671 adjuvant Substances 0.000 title claims description 19
239000000203 mixture Substances 0.000 title description 21
125000000539 amino acid group Chemical group 0.000 claims description 53
210000000612 antigen-presenting cell Anatomy 0.000 claims description 30
230000028993 immune response Effects 0.000 claims description 24
239000000126 substance Substances 0.000 claims description 19
229940046166 oligodeoxynucleotide Drugs 0.000 claims description 13
230000004936 stimulating effect Effects 0.000 claims description 13
150000001875 compounds Chemical class 0.000 claims description 11
230000003308 immunostimulating effect Effects 0.000 claims description 10
108090000695 Cytokines Proteins 0.000 claims description 9
102000004127 Cytokines Human genes 0.000 claims description 9
108020004707 nucleic acids Proteins 0.000 claims description 9
102000039446 nucleic acids Human genes 0.000 claims description 9
150000007523 nucleic acids Chemical class 0.000 claims description 9
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 5
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 5
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 5
230000002708 enhancing effect Effects 0.000 claims description 5
229960003104 ornithine Drugs 0.000 claims description 5
UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 claims description 3
VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 claims description 3
MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 claims description 3
UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 claims description 3
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 3
229930010555 Inosine Natural products 0.000 claims description 3
QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 claims description 3
QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 claims description 3
150000001408 amides Chemical class 0.000 claims description 3
UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 claims description 3
VGONTNSXDCQUGY-UHFFFAOYSA-N desoxyinosine Natural products C1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 VGONTNSXDCQUGY-UHFFFAOYSA-N 0.000 claims description 3
230000000694 effects Effects 0.000 claims description 3
150000002148 esters Chemical class 0.000 claims description 3
229960003786 inosine Drugs 0.000 claims description 3
150000007970 thio esters Chemical class 0.000 claims description 3
239000002253 acid Substances 0.000 claims description 2
MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 claims description 2
238000002360 preparation method Methods 0.000 claims description 2
102000014914 Carrier Proteins Human genes 0.000 claims 3
108010078791 Carrier Proteins Proteins 0.000 claims 3
150000001412 amines Chemical group 0.000 claims 1
210000004899 c-terminal region Anatomy 0.000 claims 1
239000003102 growth factor Substances 0.000 claims 1
229940088597 hormone Drugs 0.000 claims 1
239000005556 hormone Substances 0.000 claims 1
LQRJAEQXMSMEDP-XCHBZYMASA-N peptide a Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)NCCCC[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C/C=1C=CC=CC=1)C(N)=O)C(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C\C1=CC=CC=C1 LQRJAEQXMSMEDP-XCHBZYMASA-N 0.000 claims 1
102000004196 processed proteins & peptides Human genes 0.000 description 51
210000004027 cell Anatomy 0.000 description 33
210000001744 T-lymphocyte Anatomy 0.000 description 20
102000044503 Antimicrobial Peptides Human genes 0.000 description 18
108700042778 Antimicrobial Peptides Proteins 0.000 description 18
108090000623 proteins and genes Proteins 0.000 description 18
102000004169 proteins and genes Human genes 0.000 description 18
235000018102 proteins Nutrition 0.000 description 17
238000000034 method Methods 0.000 description 14
206010028980 Neoplasm Diseases 0.000 description 12
230000000890 antigenic effect Effects 0.000 description 12
108060001132 cathelicidin Proteins 0.000 description 12
102000014509 cathelicidin Human genes 0.000 description 12
108700018351 Major Histocompatibility Complex Proteins 0.000 description 11
150000001413 amino acids Chemical group 0.000 description 11
210000004443 dendritic cell Anatomy 0.000 description 11
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 11
229920000724 poly(L-arginine) polymer Polymers 0.000 description 10
230000000845 anti-microbial effect Effects 0.000 description 9
POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 description 9
244000052769 pathogen Species 0.000 description 8
230000008569 process Effects 0.000 description 8
238000001727 in vivo Methods 0.000 description 7
210000000440 neutrophil Anatomy 0.000 description 7
239000003910 polypeptide antibiotic agent Substances 0.000 description 7
241000282414 Homo sapiens Species 0.000 description 6
241000699670 Mus sp. Species 0.000 description 6
210000004698 lymphocyte Anatomy 0.000 description 6
210000002540 macrophage Anatomy 0.000 description 6
238000002255 vaccination Methods 0.000 description 6
208000023275 Autoimmune disease Diseases 0.000 description 5
108020004414 DNA Proteins 0.000 description 5
241001529936 Murinae Species 0.000 description 5
101500027983 Rattus norvegicus Octadecaneuropeptide Proteins 0.000 description 5
210000003719 b-lymphocyte Anatomy 0.000 description 5
239000000306 component Substances 0.000 description 5
239000012636 effector Substances 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
230000015788 innate immune response Effects 0.000 description 5
230000000813 microbial effect Effects 0.000 description 5
230000001717 pathogenic effect Effects 0.000 description 5
241000894007 species Species 0.000 description 5
241000283690 Bos taurus Species 0.000 description 4
238000011510 Elispot assay Methods 0.000 description 4
102000043129 MHC class I family Human genes 0.000 description 4
108091054437 MHC class I family Proteins 0.000 description 4
241000124008 Mammalia Species 0.000 description 4
241000251539 Vertebrata <Metazoa> Species 0.000 description 4
230000004913 activation Effects 0.000 description 4
108010051081 dopachrome isomerase Proteins 0.000 description 4
238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 4
238000000684 flow cytometry Methods 0.000 description 4
230000001900 immune effect Effects 0.000 description 4
210000000987 immune system Anatomy 0.000 description 4
230000002163 immunogen Effects 0.000 description 4
230000001939 inductive effect Effects 0.000 description 4
230000000977 initiatory effect Effects 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
230000037361 pathway Effects 0.000 description 4
230000004044 response Effects 0.000 description 4
102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 3
108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 3
241000282412 Homo Species 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
108010039918 Polylysine Proteins 0.000 description 3
230000004721 adaptive immunity Effects 0.000 description 3
239000005557 antagonist Substances 0.000 description 3
230000030741 antigen processing and presentation Effects 0.000 description 3
108010009352 antilipopolysaccharide factor (Limulus) Proteins 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
238000009566 cancer vaccine Methods 0.000 description 3
229940022399 cancer vaccine Drugs 0.000 description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
125000002091 cationic group Chemical group 0.000 description 3
230000000973 chemotherapeutic effect Effects 0.000 description 3
238000001212 derivatisation Methods 0.000 description 3
230000006698 induction Effects 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
210000001165 lymph node Anatomy 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
108010011110 polyarginine Proteins 0.000 description 3
229920002851 polycationic polymer Polymers 0.000 description 3
229920000656 polylysine Polymers 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
238000012360 testing method Methods 0.000 description 3
238000011282 treatment Methods 0.000 description 3
125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
102000004082 Calreticulin Human genes 0.000 description 2
108090000549 Calreticulin Proteins 0.000 description 2
241000233866 Fungi Species 0.000 description 2
229930186217 Glycolipid Natural products 0.000 description 2
241000711549 Hepacivirus C Species 0.000 description 2
241000725303 Human immunodeficiency virus Species 0.000 description 2
108010002350 Interleukin-2 Proteins 0.000 description 2
102000000588 Interleukin-2 Human genes 0.000 description 2
102100031413 L-dopachrome tautomerase Human genes 0.000 description 2
102000043131 MHC class II family Human genes 0.000 description 2
108091054438 MHC class II family Proteins 0.000 description 2
108010033276 Peptide Fragments Proteins 0.000 description 2
102000007079 Peptide Fragments Human genes 0.000 description 2
241000714474 Rous sarcoma virus Species 0.000 description 2
230000006044 T cell activation Effects 0.000 description 2
230000005867 T cell response Effects 0.000 description 2
230000003044 adaptive effect Effects 0.000 description 2
210000005006 adaptive immune system Anatomy 0.000 description 2
239000000556 agonist Substances 0.000 description 2
230000000844 anti-bacterial effect Effects 0.000 description 2
239000004599 antimicrobial Substances 0.000 description 2
230000001363 autoimmune Effects 0.000 description 2
244000052616 bacterial pathogen Species 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
108010007004 cathelin Proteins 0.000 description 2
238000007385 chemical modification Methods 0.000 description 2
238000009795 derivation Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000012634 fragment Substances 0.000 description 2
230000006870 function Effects 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
-1 iminothiocane Chemical compound 0.000 description 2
230000036039 immunity Effects 0.000 description 2
229960001438 immunostimulant agent Drugs 0.000 description 2
239000003022 immunostimulating agent Substances 0.000 description 2
230000002779 inactivation Effects 0.000 description 2
206010022000 influenza Diseases 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
210000005210 lymphoid organ Anatomy 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
210000000822 natural killer cell Anatomy 0.000 description 2
244000045947 parasite Species 0.000 description 2
108010091748 peptide A Proteins 0.000 description 2
238000012545 processing Methods 0.000 description 2
229940070376 protein Drugs 0.000 description 2
230000002797 proteolythic effect Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000006641 stabilisation Effects 0.000 description 2
230000002483 superagonistic effect Effects 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
108700031308 Antennapedia Homeodomain Proteins 0.000 description 1
102000014133 Antimicrobial Cationic Peptides Human genes 0.000 description 1
108010050820 Antimicrobial Cationic Peptides Proteins 0.000 description 1
241000193738 Bacillus anthracis Species 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
238000011740 C57BL/6 mouse Methods 0.000 description 1
241000222122 Candida albicans Species 0.000 description 1
229920002101 Chitin Polymers 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
201000005019 Chlamydia pneumonia Diseases 0.000 description 1
241000606153 Chlamydia trachomatis Species 0.000 description 1
108091029430 CpG site Proteins 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
108010041986 DNA Vaccines Proteins 0.000 description 1
229940021995 DNA vaccine Drugs 0.000 description 1
108010002069 Defensins Proteins 0.000 description 1
102000000541 Defensins Human genes 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
102000018997 Growth Hormone Human genes 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
241000590002 Helicobacter pylori Species 0.000 description 1
102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
108090000174 Interleukin-10 Proteins 0.000 description 1
108090000978 Interleukin-4 Proteins 0.000 description 1
108010002616 Interleukin-5 Proteins 0.000 description 1
150000008575 L-amino acids Chemical class 0.000 description 1
206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
101000924587 Mus musculus Adenomatous polyposis coli protein Proteins 0.000 description 1
241000187479 Mycobacterium tuberculosis Species 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241000425347 Phyla <beetle> Species 0.000 description 1
241001442539 Plasmodium sp. Species 0.000 description 1
229920002873 Polyethylenimine Polymers 0.000 description 1
102000002278 Ribosomal Proteins Human genes 0.000 description 1
108010000605 Ribosomal Proteins Proteins 0.000 description 1
241000702670 Rotavirus Species 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
241000191940 Staphylococcus Species 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
201000005010 Streptococcus pneumonia Diseases 0.000 description 1
241000193998 Streptococcus pneumoniae Species 0.000 description 1
OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
241000607626 Vibrio cholerae Species 0.000 description 1
241000700605 Viruses Species 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000033289 adaptive immune response Effects 0.000 description 1
230000002730 additional effect Effects 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000003502 anti-nociceptive effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000009118 appropriate response Effects 0.000 description 1
238000003556 assay Methods 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
229940065181 bacillus anthracis Drugs 0.000 description 1
239000011324 bead Substances 0.000 description 1
102000023732 binding proteins Human genes 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
229940095731 candida albicans Drugs 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000007969 cellular immunity Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
125000003636 chemical group Chemical group 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229940038705 chlamydia trachomatis Drugs 0.000 description 1
230000024203 complement activation Effects 0.000 description 1
230000002153 concerted effect Effects 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
230000016396 cytokine production Effects 0.000 description 1
210000004395 cytoplasmic granule Anatomy 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
230000007123 defense Effects 0.000 description 1
230000008260 defense mechanism Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
239000003814 drug Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000000285 follicular dendritic cell Anatomy 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
239000008187 granular material Substances 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
229940037467 helicobacter pylori Drugs 0.000 description 1
208000005252 hepatitis A Diseases 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000006054 immunological memory Effects 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000001965 increasing effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000009545 invasion Effects 0.000 description 1
210000001821 langerhans cell Anatomy 0.000 description 1
208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
239000002502 liposome Substances 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
210000001806 memory b lymphocyte Anatomy 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
230000003641 microbiacidal effect Effects 0.000 description 1
244000005706 microflora Species 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
230000001473 noxious effect Effects 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
230000000242 pagocytic effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
210000001539 phagocyte Anatomy 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
208000030773 pneumonia caused by chlamydia Diseases 0.000 description 1
229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
229920001308 poly(aminoacid) Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
150000003212 purines Chemical class 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229960001866 silicon dioxide Drugs 0.000 description 1
239000000243 solution Substances 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
230000008685 targeting Effects 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
241000712461 unidentified influenza virus Species 0.000 description 1
239000012646 vaccine adjuvant Substances 0.000 description 1
229940124931 vaccine adjuvant Drugs 0.000 description 1
229940118696 vibrio cholerae Drugs 0.000 description 1
244000052613 viral pathogen Species 0.000 description 1
230000029663 wound healing Effects 0.000 description 1
230000037314 wound repair Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Mycology (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Pulmonology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
AIDS & HIV (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

ZA200301465A 2000-10-18 2003-02-24 Vaccine composition comprising an antigen and a peptide having adjuvant properties. ZA200301465B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
AT0178900A AT410635B (de)	2000-10-18	2000-10-18	Vakzin-zusammensetzung

Publications (1)

Publication Number	Publication Date
ZA200301465B true ZA200301465B (en)	2004-02-24

Family

ID=3688953

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200301465A ZA200301465B (en)	2000-10-18	2003-02-24	Vaccine composition comprising an antigen and a peptide having adjuvant properties.

Country Status (26)

Country	Link
US (3)	US8361476B2 (de)
EP (1)	EP1326634B1 (de)
JP (2)	JP4227407B2 (de)
KR (1)	KR100598302B1 (de)
CN (1)	CN1248736C (de)
AT (2)	AT410635B (de)
AU (2)	AU1232602A (de)
BR (1)	BRPI0114994B8 (de)
CA (1)	CA2426490C (de)
CZ (1)	CZ303303B6 (de)
DE (1)	DE60119145T2 (de)
DK (1)	DK1326634T3 (de)
ES (1)	ES2263668T3 (de)
HU (1)	HU228382B1 (de)
IL (2)	IL154605A0 (de)
IS (1)	IS2608B (de)
MX (1)	MXPA03002828A (de)
NO (1)	NO330274B1 (de)
NZ (1)	NZ524532A (de)
PL (1)	PL209016B1 (de)
PT (1)	PT1326634E (de)
RU (2)	RU2328305C2 (de)
SI (1)	SI1326634T1 (de)
SK (1)	SK287618B6 (de)
WO (1)	WO2002032451A1 (de)
ZA (1)	ZA200301465B (de)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AT410635B (de) *	2000-10-18	2003-06-25	Cistem Biotechnologies Gmbh	Vakzin-zusammensetzung
WO2002053184A2 (en) *	2001-01-05	2002-07-11	Intercell Ag	Uses for polycationic compounds as vaccine adjuvants
US7244438B2 (en)	2001-01-05	2007-07-17	Intercell Ag	Uses for polycationic compounds
AT410798B (de)	2001-01-26	2003-07-25	Cistem Biotechnologies Gmbh	Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
EP1279404A1 (de)	2001-07-26	2003-01-29	Istituto Superiore di Sanità	Verwendung von HIV-1 Fragmenten oder Derivaten zur Bestimmung oder Aktivierung von Antigen-präsentierenden Zellen, oder zur Abgabe von Cargo-Molekülen für Impfung oder für Behandlung von anderen Erkrankungen
MX339524B (es)	2001-10-11	2016-05-30	Wyeth Corp	Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
WO2004011650A2 (en)	2002-07-24	2004-02-05	Intercell Ag	Antigens encoded by alternative reading frame from pathogenic viruses
US7785608B2 (en)	2002-08-30	2010-08-31	Wyeth Holdings Corporation	Immunogenic compositions for the prevention and treatment of meningococcal disease
WO2004024182A2 (en)	2002-09-13	2004-03-25	Intercell Ag	Method for isolating hepatitis c virus peptides
JP5116971B2 (ja)	2002-10-15	2013-01-09	インターセルアーゲー	Ｂ群連鎖球菌の接着因子をコードする核酸、ｂ群連鎖球菌の接着因子、およびその使用
EP2287315A1 (de)	2003-03-04	2011-02-23	Intercell AG	Streptococcus-pyogenes-Antigene
CN1764473A (zh) *	2003-03-24	2006-04-26	英特塞尔股份公司	矾与Th1免疫应答诱导佐剂用于增强免疫应答的用途
EP1608402B1 (de) *	2003-03-24	2010-10-20	Intercell AG	Verbesserte impfstoffe
JP2007523609A (ja)	2003-03-31	2007-08-23	インターツェル・アクチェンゲゼルシャフト	表皮ブドウ球菌抗原
EP2311988A1 (de)	2003-04-15	2011-04-20	Intercell AG	S. pneumoniae-Antigene
US8076059B2 (en) *	2003-04-16	2011-12-13	Duke University	Adjuvant capable of specifically activating the adaptive immune response
EP2289907A3 (de)	2003-05-07	2011-08-31	Intercell AG	Streptococcus agalactiae-Antigene I + II
US20080175856A1 (en)	2003-05-30	2008-07-24	Intercell Ag	Enterococcus Antigens
JP4734241B2 (ja) *	2003-07-11	2011-07-27	インターツェル・アクチェンゲゼルシャフト	Ｈｃｖワクチン
US20080145383A1 (en)	2004-03-12	2008-06-19	Intercell Ag	Method for Solubilizing Peptide Mixtures
EP2149583B1 (de)	2004-09-24	2015-10-28	Novartis AG	Modifiziertes VP1-Capsid Protein von Parvovirus B19
EP1931379B1 (de)	2005-10-07	2013-05-29	Health Protection Agency	Proteine mit verbesserter löslichkeit und herstellungs- und anwendungsverfahren
TW200806315A (en)	2006-04-26	2008-02-01	Wyeth Corp	Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
EP2040745B1 (de)	2006-06-28	2012-12-05	Statens Serum Institut	Expansion des t-zell-repertoirs, um subdominante epitope durch impfung mit antigenen, die als proteinfragmente oder peptidcocktails abgegeben werden, aufzunehmen
EP2292644A3 (de)	2006-07-07	2011-05-25	Intercell AG	Kleine Streptococcus-pyogenes-Antigene und Verwendung dafür
JP2010503384A (ja)	2006-09-15	2010-02-04	インターセルアーゲー	ボレリア（Ｂｏｒｒｅｌｉａ）抗原
EP1923069A1 (de)	2006-11-20	2008-05-21	Intercell AG	Schutzpeptide gegen S. pneumoniae und diesbezügliche Zusammensetzungen, Verfahren und Verwendungen
AR064642A1 (es)	2006-12-22	2009-04-15	Wyeth Corp	Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
CA2675379A1 (en)	2007-01-12	2008-07-17	Intercell Ag	Protective proteins of s. agalactiae, combinations thereof and methods of using the same
CN102015754A (zh)	2007-05-02	2011-04-13	英特塞尔股份公司	克雷伯菌（Klebsiella）抗原
EP2012122A1 (de)	2007-07-06	2009-01-07	Medigene AG	Strukturproteine von mutierten Parvoviren als Impfstoffe
ES2602610T3 (es)	2007-05-31	2017-02-21	Medigene Ag	Proteína estructural mutada de un parvovirus
CN101883782A (zh)	2007-06-18	2010-11-10	英特塞尔股份公司	衣原体抗原
AU2009226949A1 (en)	2008-03-17	2009-09-24	Intercell Ag	Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
WO2009123119A1 (ja)	2008-04-02	2009-10-08	国立大学法人徳島大学	合成ペプチドを含有する抗原薬物ビークルとこれを用いる粘膜ワクチン
EP2650014A2 (de)	2008-06-20	2013-10-16	Wyeth LLC	Zusammensetzungen und Verfahren zur Verwendung von ORF1358 von Beta-hämolytischen Streptokokken-stämmen
US20100015171A1 (en) *	2008-07-15	2010-01-21	Statens Serum Institute	Vaccines comprising tb 10.4
US20130243779A1 (en)	2009-02-05	2013-09-19	Intercell Ag	Peptides protective against e. faecalis, methods and uses relating thereto
EP2405938A2 (de)	2009-02-13	2012-01-18	Intercell AG	Nicht typisierbare haemophilus influenza-antigene
SG10201406432RA (en)	2009-06-22	2014-11-27	Wyeth Llc	Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
SA110310528B1 (ar)	2009-06-22	2014-07-02	Wyeth Llc	التركيبات المولدة للمناعة لأنتيجينات ستافيلوكوكس أوريس
EP2470205A1 (de)	2009-08-27	2012-07-04	Novartis AG	Hilfsstoff mit aluminium, oligonukleotid und polykation
KR20120089863A (ko)	2009-10-09	2012-08-14	사노피	“개선된 당화반응 최종 생성물에 대한 수용체”에 결합하기 위한 폴리펩타이드 및 이를 포함하는 조성물 및 방법
EP2308896A1 (de)	2009-10-09	2011-04-13	Sanofi-aventis	Polypeptides zum Binden an den Rezeptor für weiterentwickelte Glykierungsendprodukte sowie Zusammensetzungen und Verfahren, die diese Polypeptide beinhalten
EP2319871A1 (de)	2009-11-05	2011-05-11	Sanofi-aventis	Polypeptide zum Binden an den Rezeptor für weiterentwickelte Glykierungsendprodukte sowie Zusammensetzungen und Verfahren, die diese Polypeptide beinhalten
WO2011101465A1 (en)	2010-02-19	2011-08-25	Intercell Ag	Ic31 nanoparticles
AU2011288203A1 (en)	2010-03-18	2012-08-23	Novartis Ag	Adjuvanted vaccines for serogroup B meningococcus
PL2575870T3 (pl)	2010-06-04	2017-05-31	Wyeth Llc	Preparaty szczepionek
CN107913396B (zh)	2010-08-23	2022-03-08	惠氏有限责任公司	脑膜炎萘瑟氏菌rLP2086抗原的稳定制剂
PL2753352T5 (pl)	2010-09-03	2022-10-17	Valneva Austria Gmbh	Izolowany polipeptyd białek toksyny a i toksyny b z c. difficile i jego zastosowania
AR082925A1 (es)	2010-09-08	2013-01-16	Medigene Ag	Proteinas estructurales mutadas por parvovirus con epitopo de celulas b de proteccion cruzada, producto y metodos relacionados
AU2011300409B2 (en)	2010-09-10	2015-03-26	Wyeth Llc	Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
EP2654784B1 (de)	2010-12-22	2016-12-07	Wyeth LLC	Stabile immunogene zusammensetzungen aus staphylococcus aureus-antigenen
BRPI1100857A2 (pt) *	2011-03-18	2013-05-21	Eduardo Nowill Alexandre	agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real
ITMI20111182A1 (it)	2011-06-28	2012-12-29	Canio Buonavoglia	Vaccino per coronavirus canino
SA115360586B1 (ar)	2012-03-09	2017-04-12	فايزر انك	تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY198910A (en)	2012-03-09	2023-10-02	Pfizer	Neisseria meningitidis compositions and methods thereof
CN104428411B (zh) *	2012-05-08	2018-11-23	健康科学西部大学	用于cd4+t细胞群之抗原特异性扩增的标准化离体平台
US20150297714A1 (en) *	2012-10-29	2015-10-22	The Board Of Trustees Of The University Of Arkansas	Novel mucosal adjuvants and delivery systems
JP6502262B2 (ja)	2012-12-20	2019-04-17	ファイザー・インク	糖複合化方法
WO2014136064A2 (en)	2013-03-08	2014-09-12	Pfizer Inc.	Immunogenic fusion polypeptides
US20140271723A1 (en) *	2013-03-15	2014-09-18	Saint Louis University	Adjuvant compositions and methods of using thereof
RU2662968C2 (ru)	2013-09-08	2018-07-31	Пфайзер Инк.	Иммуногенная композиция против neisseria meningitidis (варианты)
WO2016130569A1 (en)	2015-02-09	2016-08-18	Mj Biologics, Inc.	A composition comprising pedv antigens and methods for making and using the composition
WO2016132294A1 (en)	2015-02-19	2016-08-25	Pfizer Inc.	Neisseria meningitidis compositions and methods thereof
MY182282A (en)	2015-05-04	2021-01-18	Pfizer	Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
CN113521007B (zh) *	2016-07-01	2022-11-18	四川大学	抗菌肽衍生物在制备免疫佐剂中的用途
US10751402B2 (en)	2016-11-09	2020-08-25	Pfizer Inc.	Immunogenic compositions and uses thereof
AU2018215585B2 (en)	2017-01-31	2022-03-17	Pfizer Inc.	Neisseria meningitidis compositions and methods thereof
WO2018187515A1 (en) *	2017-04-04	2018-10-11	Avidea Technologies, Inc.	Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
CN107266585B (zh) *	2017-07-13	2019-08-06	陕西科技大学	一种mlh融合抗菌肽及其制备方法和应用
AU2019220386A1 (en)	2018-02-16	2020-08-20	2A Pharma Ab	Parvovirus structural protein for the treatment of autoimmune diseases
EP3527223A1 (de)	2018-02-16	2019-08-21	2A Pharma AB	Mutiertes parvovirus-strukturprotein
CN109745556A (zh) *	2019-03-01	2019-05-14	龙阔（苏州）生物工程有限公司	一种疫苗佐剂及其应用及猪繁殖与呼吸综合征疫苗
EP3972639A1 (de)	2019-05-20	2022-03-30	Valneva SE	Subunit-impfstoff zur behandlung oder vorbeugung einer atemwegsinfektion
WO2021059181A1 (en)	2019-09-27	2021-04-01	Pfizer Inc.	Neisseria meningitidis compositions and methods thereof
WO2021202456A1 (en) *	2020-03-30	2021-10-07	The Wistar Institute Of Anatomy And Biology	Synthetic soluble receptor mimics and methods of use for treatment of covid-19
EP4136095A1 (de)	2020-04-17	2023-02-22	Regents of the University of Minnesota	Sars-cov-2-spike-rezeptorbindungsdomäne und zusammensetzungen und verfahren dafür
KR20230056727A (ko)	2020-08-26	2023-04-27	화이자 인코포레이티드	B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도
KR20230167017A (ko)	2021-04-09	2023-12-07	발네바 에스이	인간 메타뉴모 바이러스 백신
WO2023083964A1 (en)	2021-11-11	2023-05-19	2A Pharma Ab	Parvovirus structural protein against beta- and gamma-hpv
WO2024069420A2 (en)	2022-09-29	2024-04-04	Pfizer Inc.	Immunogenic compositions comprising an rsv f protein trimer
WO2026038177A1 (en)	2024-08-16	2026-02-19	Pfizer Inc.	Immunogenic compositions and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH09502086A (ja) *	1993-08-06	1997-03-04	サイテルコーポレイション	完全ｍａｇｅ１遺伝子のクローニング及び特性決定
JP3442824B2 (ja) *	1993-08-30	2003-09-02	理化学研究所	抗菌性ペプチド類
JP3547504B2 (ja) *	1994-11-01	2004-07-28	独立行政法人理化学研究所	新規なポリペプチド及びその用途
CA2293826A1 (en)	1997-06-11	1998-12-17	Brigitte Gicquel	Attenuated recombinant mycobacteria useful as immunogens or as vaccine components
US6312731B1 (en)	1997-08-29	2001-11-06	Southern Research Institute	Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of using thereof
CU22700A1 (es) *	1997-09-29	2001-07-31	Ct Ingenieria Genetica Biotech	Formulación farmacéutica anti-viral que contiene un péptido de la proteína factor anti-lps de limulus y su uso
US20020072495A1 (en) *	2000-09-21	2002-06-13	Oleg Chertov	LL-37 is an immunostimulant
AT410635B (de)	2000-10-18	2003-06-25	Cistem Biotechnologies Gmbh	Vakzin-zusammensetzung
EP1608402B1 (de)	2003-03-24	2010-10-20	Intercell AG	Verbesserte impfstoffe
CN1764473A (zh)	2003-03-24	2006-04-26	英特塞尔股份公司	矾与Th1免疫应答诱导佐剂用于增强免疫应答的用途
JP4734241B2 (ja)	2003-07-11	2011-07-27	インターツェル・アクチェンゲゼルシャフト	Ｈｃｖワクチン

2000
- 2000-10-18 AT AT0178900A patent/AT410635B/de not_active IP Right Cessation
2001
- 2001-10-18 AU AU1232602A patent/AU1232602A/xx active Pending
- 2001-10-18 AU AU2002212326A patent/AU2002212326B2/en not_active Expired
- 2001-10-18 NZ NZ524532A patent/NZ524532A/en not_active IP Right Cessation
- 2001-10-18 CN CNB018171168A patent/CN1248736C/zh not_active Expired - Lifetime
- 2001-10-18 BR BRPI0114994-6 patent/BRPI0114994B8/pt not_active IP Right Cessation
- 2001-10-18 DK DK01980496T patent/DK1326634T3/da active
- 2001-10-18 EP EP01980496A patent/EP1326634B1/de not_active Expired - Lifetime
- 2001-10-18 WO PCT/EP2001/012041 patent/WO2002032451A1/en not_active Ceased
- 2001-10-18 PT PT01980496T patent/PT1326634E/pt unknown
- 2001-10-18 JP JP2002535688A patent/JP4227407B2/ja not_active Expired - Lifetime
- 2001-10-18 PL PL362966A patent/PL209016B1/pl unknown
- 2001-10-18 CZ CZ20031299A patent/CZ303303B6/cs not_active IP Right Cessation
- 2001-10-18 SK SK575-2003A patent/SK287618B6/sk not_active IP Right Cessation
- 2001-10-18 MX MXPA03002828A patent/MXPA03002828A/es active IP Right Grant
- 2001-10-18 DE DE60119145T patent/DE60119145T2/de not_active Expired - Lifetime
- 2001-10-18 KR KR1020037004977A patent/KR100598302B1/ko not_active Expired - Lifetime
- 2001-10-18 ES ES01980496T patent/ES2263668T3/es not_active Expired - Lifetime
- 2001-10-18 US US10/399,442 patent/US8361476B2/en active Active
- 2001-10-18 IL IL15460501A patent/IL154605A0/xx unknown
- 2001-10-18 AT AT01980496T patent/ATE324116T1/de not_active IP Right Cessation
- 2001-10-18 SI SI200130564T patent/SI1326634T1/sl unknown
- 2001-10-18 CA CA2426490A patent/CA2426490C/en not_active Expired - Lifetime
- 2001-10-18 HU HU0302117A patent/HU228382B1/hu unknown
- 2001-10-18 RU RU2003114434/15A patent/RU2328305C2/ru active
2003
- 2003-02-20 IS IS6722A patent/IS2608B/is unknown
- 2003-02-24 IL IL154605A patent/IL154605A/en unknown
- 2003-02-24 ZA ZA200301465A patent/ZA200301465B/en unknown
- 2003-04-08 NO NO20031595A patent/NO330274B1/no not_active IP Right Cessation
2007
- 2007-12-13 RU RU2007146372/15A patent/RU2007146372A/ru not_active Application Discontinuation
2008
- 2008-05-21 US US12/124,785 patent/US8900564B2/en not_active Expired - Lifetime
- 2008-05-22 JP JP2008134215A patent/JP2008222721A/ja not_active Withdrawn
2013
- 2013-01-16 US US13/742,500 patent/US20130216583A1/en not_active Abandoned

Also Published As

Publication number	Publication date
PT1326634E (pt)	2006-09-29
EP1326634B1 (de)	2006-04-26
ATE324116T1 (de)	2006-05-15
NO330274B1 (no)	2011-03-14
NZ524532A (en)	2004-10-29
BR0114994A (pt)	2003-09-30
BRPI0114994B1 (pt)	2017-11-07
ATA17892000A (de)	2002-11-15
HUP0302117A2 (hu)	2003-09-29
AT410635B (de)	2003-06-25
WO2002032451A1 (en)	2002-04-25
ES2263668T3 (es)	2006-12-16
SK287618B6 (sk)	2011-04-05
CN1468109A (zh)	2004-01-14
IL154605A (en)	2009-05-04
CN1248736C (zh)	2006-04-05
NO20031595L (no)	2003-06-05
US20050063978A1 (en)	2005-03-24
JP4227407B2 (ja)	2009-02-18
US20130216583A1 (en)	2013-08-22
KR100598302B1 (ko)	2006-07-07
MXPA03002828A (es)	2003-07-14
PL362966A1 (en)	2004-11-02
DE60119145D1 (de)	2006-06-01
PL209016B1 (pl)	2011-07-29
HUP0302117A3 (en)	2004-11-29
US8361476B2 (en)	2013-01-29
HK1055899A1 (en)	2004-01-30
CZ303303B6 (cs)	2012-07-25
RU2007146372A (ru)	2009-06-20
RU2328305C2 (ru)	2008-07-10
CZ20031299A3 (cs)	2003-10-15
SK5752003A3 (en)	2003-12-02
HU228382B1 (en)	2013-03-28
EP1326634A1 (de)	2003-07-16
IS2608B (is)	2010-04-15
AU2002212326B2 (en)	2006-01-05
JP2004511528A (ja)	2004-04-15
SI1326634T1 (sl)	2006-10-31
CA2426490C (en)	2012-01-31
KR20030043993A (ko)	2003-06-02
JP2008222721A (ja)	2008-09-25
DE60119145T2 (de)	2007-02-01
AU1232602A (en)	2002-04-29
US20090123486A1 (en)	2009-05-14
NO20031595D0 (no)	2003-04-08
DK1326634T3 (da)	2006-08-14
CA2426490A1 (en)	2002-04-25
WO2002032451A8 (en)	2002-05-23
US8900564B2 (en)	2014-12-02
BRPI0114994B8 (pt)	2021-05-25
IL154605A0 (en)	2003-09-17
IS6722A (is)	2003-02-20

Publication	Publication Date	Title
CA2426490C (en)	2012-01-31	Vaccine composition comprising an antigen and a peptide having adjuvant properties
AU2002212326A1 (en)	2002-07-04	Vaccine composition comprising an antigen and a peptide having adjuvant properties
JP2008222721A6 (ja)	2008-12-11	ワクチン組成物
AU784403B2 (en)	2006-03-30	Pharmaceutical composition for immunomodulation and preparation of vaccines comprising an antigen and an immunogenic oligodeoxynucleotide and a polycationic polymer as adjuvants
AU2001289813A1 (en)	2002-05-23	A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
EP1272215A2 (de)	2003-01-08	Modifizierte peptide enthaltende pharmazeutische präparationen
US20070041998A1 (en)	2007-02-22	Use of alum and a th1 immune response inducing adjuvant for enhancing immune responses
HK1055899B (en)	2006-12-01	Vaccine composition comprising an antigen and a peptide having adjuvant properties
JP2004519452A (ja)	2004-07-02	ポリカチオン性化合物の用途
AU2002340561B2 (en)	2007-11-15	Use of peptide vectors to improve the immune response to antigens